Epivir
Trovati 7 articoli
- HIV drugs: Abacavir and Didanosine increase the risk of myocardial infarction
- A study to assess the adverse effects of anti-retroviral drugs has shown that two widely-used HIV drugs are associated with an increased risk of myocardial infarction and formation of blood clots in the heart. With the use of Didanosine ( Videx ), the risk of developing a myocardial infarction in... (Leggi Articolo)
- Increased risk of myocardial infarction in HIV-1 infected patients treated with Ziagen and Videx
- The FDA ( Food and Drug Administration ) has been made aware of recent findings from analyses of data collected from " The Data Collection on Adverse Events of Anti-HIV Drugs ( D:A:D ) Study ". The D:A:D Study is a large observational study of 33,347 HIV-1 infected patients living in North Amer... (Leggi Articolo)
- Viread more effective than Hepsera in patients with chronic hepatitis B
- Studies 102 and 103 have compared Viread ( Tenofovir disoproxil ) to Hepsera ( Adefovir dipivoxil ) among patients with HBeAg-negative chronic hepatitis B and patients with HBeAg-positive hepatitis B, respectively. Results from both studies show that patients with chronic hepatitis B who receiv... (Leggi Articolo)
- Epivir to prevent hepatitis B relapse during chemotherapy
- A study on treating hepatitis B patients who have cancer with an antiviral drug at the same time as they undergo chemotherapy found that the treatment helped prevent relapse of hepatitis B. Patients who develop hepatocellular carcinoma ( HCC ), a type of liver cancer caused by the hepatitis B ... (Leggi Articolo)
- Liver transplant can be successful in HIV patients with hepatitis B
- A study on HIV patients who also had hepatitis B virus ( HBV ) found that better outcomes are possible if they are referred early for transplant and treated with a combination of drugs for HBV. It is essential to monitor the HBV status of these patients, however, in order to control the emergen... (Leggi Articolo)
- Pegasys as a first-line therapy in chronic hepatitis B
- Patients with the most common form of hepatitis B in the United States who are treated with Pegasys ( Peginterferon alfa-2a ) are more likely to achieve a sustained response than those treated with Lamivudine ( Epivir ), the current standard of care. In a Phase III study patients treated with ... (Leggi Articolo)
- Sebivo has achieved primary endpoint in GLOBE trial in patients with chronic hepatitis B
- The phase III GLOBE trial for Telbivudine ( Sebivo, Tyzeka ) successfully reached its primary, composite efficacy endpoint of therapeutic response at one year in chronic hepatitis B patients. This endpoint, which was designed to assess if Telbivudine was at least as effective as Lamivudine ( Ep... (Leggi Articolo)
